PTC to sell royalties on blockbuster SMA drug Evrysdi for up to $1.5B

PTC Ther­a­peu­tics on Thurs­day an­nounced an agree­ment with Roy­al­ty Phar­ma to mon­e­tize up to $1.5 bil­lion of the roy­al­ty stream for the spinal mus­cu­lar at­ro­phy drug Evrys­di (ris­diplam), which is al­so owned by Roche’s Genen­tech.

As part of the agree­ment, Roy­al­ty Phar­ma will ac­quire ad­di­tion­al roy­al­ties on Evrys­di for $1 bil­lion up front, PTC said in a press re­lease. PTC has the op­tions to sell its re­tained roy­al­ties for up to $500 mil­lion or for Roy­al­ty Phar­ma to ac­quire half of its re­tained roy­al­ties for up to $250 mil­lion at a lat­er date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.